Advertisement

Organisation › Details
SanReno Therapeutics (CN)
SanReno Therapeutics is a leading clinical-stage enterprise specializing in the strategic development, exploration, and commercialization of revolutionary therapies tailored for kidney diseases. Our key assets focus on treating Immunoglobulin A Nephropathy (IgAN). Atrasentan, an oral endothelian A receptor antagonist (ERA), has reached Phase 3 with success in reducing proteinuria. Zigakibart, our anti-APRIL (A Proliferation Inducing Ligand) antibody, received regulatory approval for Phase 3 studies. SanReno is dedicated to delivering transformative medicines for critical unmet needs in kidney disease therapeutics, driving advancements and setting new benchmarks in the field. Established in late 2021 as a joint venture between the investor consortium and Chinook Therapeutics (now part of Novartis), SanReno holds exclusive rights in Greater China and Singapore for two late-stage assets targeting Immunoglobulin A Nephropathy (IgAN): atrasentan and zigakibart. Atrasentan, an oral endothelin A receptor antagonist (ERA), is presently undergoing Phase 3 development for IgAN. It demonstrated clinically meaningful and highly statistically significant proteinuria reduction at the 36-weeks interim analysis, successfully meeting the primary endpoint of its Phase 3 study. Zigakibart (BION-1301), a subcutaneously administered monoclonal antibody targeting APRIL (A Proliferation Inducing Ligand), obtained approval from China CDE for entry into the Phase 3 study in October 2023. *
![]() |
Start | 2021-12-01 established jv |
![]() |
Person | Huang, Haoyu (James) (SanReno Therapeutics 202401 CEO before Takeda China + Baxter Greater China + AbbVie Taiwan) |
![]() |
Region | Shanghai |
Country | China | |
City | n. a. Shanghai | |
Address record changed: 2024-01-17 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: SanReno Therapeutics. (1/5/24). "Press Release: SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease". Shanghai. | ||
Record changed: 2024-09-22 |
Advertisement

More documents for Novartis (Group)
- [1] Eckert & Ziegler SE. (12/13/24). "Press Release: Eckert & Ziegler Submits GalliaPharm for Approval by Japan’s Health Authority MHLW". Berlin....
- [2] PeptiDream Inc.. (4/30/24). "Press Release: PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis". Kanagawa....
- [3] Scinai Immunotherapeutics Ltd.. (2/13/24). "Press Release: Scinai Welcomes Liat Halpert as Head of Business Development and Sales". Jerusalem....
- [4] Shanghai Argo Biopharmaceutical Co., Ltd.. (1/7/24). "Press Release: Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis". Shanghai....
- [5] SanReno Therapeutics. (1/5/24). "Press Release: SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease". Shanghai....
- [6] Legend Biotech Corporation. (11/13/23). "Press Release: Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3". Somerset, NJ....
- [7] Sandoz Group AG. (10/4/23). "Press Release: Sandoz Enters New Era as Standalone Global Leader and European Champion in Generic and Biosimilar Medicines". Basel....
- [8] BeiGene, Ltd.. (9/19/23). "Press Release: BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody Tevimbra (tislelizumab)". Basel & Beijing & Cambridge, MA....
- [9] Novartis AG. (9/11/23). "Press Release: Sandoz Announces Exclusive Deal to Commercialize Biosimilar Ustekinumab". Basel....
- [10] BioGeneration Ventures B.V.. (7/19/23). "Press Release: Dr. Markus Kalousek and Dr. Andrew Lightfoot Join BGV as Venture Partners". Amsterdam....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top